Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.

[1]  S. Stanojevic,et al.  Normative multiple-breath washout data in school-aged children corrected for sensor error , 2022, European Respiratory Journal.

[2]  H. Grasemann,et al.  How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease be Monitored? , 2022, American journal of respiratory and critical care medicine.

[3]  H. Kauczor,et al.  Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis. , 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[4]  G. Sawicki,et al.  A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. , 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[5]  M. Revel,et al.  Using chest computed tomography and unsupervised machine learning for predicting and evaluating response to lumacaftor–ivacaftor in people with cystic fibrosis , 2021, European Respiratory Journal.

[6]  O. Sommerburg,et al.  Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles , 2021, American Journal of Respiratory and Critical Care Medicine.

[7]  K. Ramsey,et al.  Correction of sensor crosstalk error in Exhalyzer D multiple-breath washout device significantly impacts outcomes in children with cystic fibrosis. , 2021, Journal of applied physiology.

[8]  O. Bieri,et al.  Defect distribution index: A novel metric for functional lung MRI in cystic fibrosis , 2021, Magnetic resonance in medicine.

[9]  H. Kauczor,et al.  Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis. , 2021, Annals of the American Thoracic Society.

[10]  G. Sawicki,et al.  Tribulations and (clinical) trials in cystic fibrosis. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[11]  K. Ramsey,et al.  Longitudinal course of clinical lung clearance index in children with cystic fibrosis , 2020, European Respiratory Journal.

[12]  F. Laurent,et al.  The Clinical Use of Lung MRI in Cystic Fibrosis , 2020, Chest.

[13]  S. Nevitt,et al.  Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). , 2020, The Cochrane database of systematic reviews.

[14]  M. Griese,et al.  Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial , 2020, American journal of respiratory and critical care medicine.

[15]  P. Cattin,et al.  The impact of segmentation on whole‐lung functional MRI quantification: Repeatability and reproducibility from multiple human observers and an artificial neural network , 2020, Magnetic resonance in medicine.

[16]  H. Kauczor,et al.  Current state of the art MRI for the longitudinal assessment of cystic fibrosis , 2019, Journal of magnetic resonance imaging : JMRI.

[17]  C. Teneback,et al.  Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial , 2019, The Lancet.

[18]  L. Lands,et al.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.

[19]  Kevin McCarthy,et al.  Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement , 2019, American journal of respiratory and critical care medicine.

[20]  O. Bieri,et al.  Ventilation and perfusion assessed by functional MRI in children with CF: reproducibility in comparison to lung function. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[21]  O. Bieri,et al.  Structural and Functional Lung Impairment in Primary Ciliary Dyskinesia. Assessment with Magnetic Resonance Imaging and Multiple Breath Washout in Comparison to Spirometry , 2018, Annals of the American Thoracic Society.

[22]  J. Davies,et al.  Disease-modifying drug therapy in cystic fibrosis. , 2017, Paediatric respiratory reviews.

[23]  Oliver Bieri,et al.  Novel magnetic resonance technique for functional imaging of cystic fibrosis lung disease , 2017, European Respiratory Journal.

[24]  John P Mugler,et al.  Use of hyperpolarized helium-3 MRI to assess response to ivacaftor treatment in patients with cystic fibrosis. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[25]  Margaret Rosenfeld,et al.  Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation , 2017, The Journal of pediatrics.

[26]  Oliver Bieri,et al.  Matrix pencil decomposition of time‐resolved proton MRI for robust and improved assessment of pulmonary ventilation and perfusion , 2017, Magnetic resonance in medicine.

[27]  Oliver Bieri,et al.  Ultra‐fast Steady‐State Free Precession Pulse Sequence for Fourier Decomposition Pulmonary MRI , 2016, Magnetic resonance in medicine.

[28]  Janet Stocks,et al.  Consensus statement for inert gas washout measurement using multiple- and single- breath tests , 2013, European Respiratory Journal.

[29]  S. Stanojevic,et al.  Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.

[30]  Annette Kopp-Schneider,et al.  Morphologic and functional scoring of cystic fibrosis lung disease using MRI. , 2012, European journal of radiology.

[31]  B. Efron,et al.  Bootstrap confidence intervals , 1996 .